Table 3.
Known-groups validity of the Acro-TSQ, second study
| Grouped by AIS overall score | |||||
|---|---|---|---|---|---|
| Acro-TSQ scale | AIS overall score group | Significance | Eta-Squared | ||
| Low 0–3 | Medium 4–7 | High > 7 | |||
|
Symptom interference (mean, SD, N) |
86 (21) N = 29 |
66 (23) N = 30 |
61 (26) N = 23 |
F = 8.9; df = 2, 79; p < .001 |
0.18 |
|
Treatment convenience (mean, SD, N) |
72 (18) N = 29 |
69 (22) N = 30 |
59 (22) N = 23 |
F = 2.7; df = 2, 79; p = .071 |
0.07 |
|
Injection site interference (mean, SD, N) |
89 (15) N = 29 |
88 (15) N = 30 |
72 (27) N = 23 |
F = 6.3; df = 2, 79; p = .003 |
0.14 |
|
GI interference (mean, SD, N) |
88 (18) N = 29 |
84 (21) N = 30 |
66 (28) N = 23 |
F = 6.7; df = 2, 79; p = .002 |
0.15 |
|
Treatment satisfaction (mean, SD, N) |
70 (16) N = 29 |
60 (13) N = 30 |
52 (26) N = 23 |
F = 6.2; df = 2, 79; p = .003 |
0.14 |
|
Emotional reaction (mean, SD, N) |
87 (17) N = 29 |
81 (19) N = 30 |
69 (29) N = 23 |
F = 4.5; df = 2, 79; p = .014 |
0.10 |
AIS Acromegaly Index of Severity, Df degree of freedom, GI gastrointestinal, SD standard deviation